Pemivibart Shows Promise as Preventive Treatment for COVID-19, suggests study
A new study published in Clinical Infectious Diseases highlights the potential of pemivibart, a long-acting monoclonal antibody, as a preventive therapy for COVID-19. Researchers evaluated the safety and efficacy of pemivibart in a phase 3 randomized controlled trial involving uninfected adults who were at increased risk of SARS-CoV-2 exposure.
The results showed that a single intramuscular dose of pemivibart significantly reduced the risk of symptomatic COVID-19 over a follow-up period of several months.
The antibody was well tolerated by participants, with adverse events comparable to those observed in the placebo group. Importantly, the study noted that the protective effects were maintained even as new variants of the virus circulated, underscoring the potential for pemivibart to serve as a robust option for pre-exposure prophylaxis-especially among immunocompromised individuals or those for whom vaccination offers limited protection.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.